What's Going On With Cardio Diagnostics Stock?
Portfolio Pulse from Ryan Gustafson
Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO) shares traded lower after the company announced that Family Medicine Specialists (FMS) has selected its epigenetic-genetic tests for identifying patients at risk for coronary heart disease. FMS plans to use the Epi+Gen CHD test on at least 1,200 patients with CHD risk factors. The stock experienced an above-average trading volume of 81.05 million shares compared to its average volume of 7.36 million.
November 08, 2023 | 11:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cardio Diagnostics' stock traded lower after the announcement of its tests being selected by FMS. The stock also saw an unusually high trading volume.
The news of FMS selecting Cardio Diagnostics' tests for CHD risk assessment is directly related to the company. However, despite this positive development, the stock traded lower, possibly due to market dynamics or other factors not mentioned in the article. The unusually high trading volume indicates increased investor interest, which could lead to increased volatility in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100